Systematic review assesses disease progression and outcomes in renal oncocytoma patients, indicating varied malignancy potential.
Introduction and Aim Benign kidney neoplasms are the term used to describe oncocytomas. They have a great prognosis and are rarely associated with an aggressive clinical course. It has been demonstrated that the illness can spread to the bones and liver. Oncocytoma metastases to the liver and lungs have also been documented in some literature. Malignancy evidence for Renal Oncocytomas (ROs) were evaluated in this systematic review. Methods This review was carried out in accordance with the protocol, which was created cooperatively and endorsed by all authors, and the PRISMA standards. The risk of bias was evaluated. Results There were 412 ROs in all from the 17 papers that were examined. Every patient who died from their condition had indications of disease progression. Overall, six patients (1.5%) had disease progression. Twenty percent of the patients had partial nephrectomy, and three hundred and seventeen patients (80%) had radical nephrectomy. The metastases included the liver, lung, bone, lymphadenopathy, and local recurrence. Metastatic behaviour has been identified as characterized by vascular invasion, renal capsular invasion, renal sinus fat invasion, and perinephric fat invasion. However, the modest number of patients who died or had their disease progressed due to ROs suggests that aggressive malignant behaviour is not always associated with the presence of disease or metastatic characteristics. Conclusion Rather than being considered benign, oncocytomas should be considered to have a minimal propensity for malignancy. The prognosis is unusually favourable for those who display aggressive traits, such as vascular invasion and/or perinephric fat invasion.
No takes yet. Share an insight, caveat, or question.
Kapilraj Ravendran (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: